Injectable GLP-1 agonists give your body that stronger, longer-lasting signal to: Reduce appetite Manage blood glucose Support gradual, sustainable weight loss Who is GLP-1 Recommended For
The AngioSafe 1 study, which is also designed to clarify the association between exposure to GLP-1R agonists and diabetic retinopathy through clinical and preclinical study designs found no risk for severe diabetic retinopathy when patients were treated with GLP-1R agonists, and no effect of GLP-1R agonists on angiogenesis (Gaborit et al., 2020)
These are vendor and community figures for laboratory research settings, not validated human clinical doses, and this article is not dosing guidance
Last reviewed: July 6, 2026 Last updated: July 6, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations